2022
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC
Kim SY, Herbst RS. BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC. Nature Reviews Clinical Oncology 2022, 20: 3-4. PMID: 36271141, DOI: 10.1038/s41571-022-00698-y.Peer-Reviewed Original ResearchConceptsCell lung cancerTumor mutational burdenLung cancerMutational burdenBlood-based tumor mutational burdenAdvanced-stage solid tumorsFirst phase III trialHigh tumor mutational burdenImmune checkpoint inhibitorsPhase III trialsIII trialsPredictive biomarkersExploratory biomarkersCompanion biomarkersSolid tumorsBiomarkersCancerBurdenPembrolizumabNSCLCPatientsTumorsTrials
2020
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials
Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clinical Radiology 2020, 76: 155.e25-155.e34. PMID: 33268083, DOI: 10.1016/j.crad.2020.09.024.Peer-Reviewed Original ResearchConceptsInterventional radiologistsClinical trial teamsTrial teamPercutaneous image-guided biopsyLung Cancer EliminationLung cancer trialsEvidence of viabilityImage-guided biopsyLesion scoring systemBiomarker analysisCancer trialsTargeted therapyCancer eliminationScore's abilityInterventional radiologyMultivariate analysisLesionsBiopsySolid massFollowing criteriaModerate agreementMultidisciplinary approachTrialsScoresBiomarkersFrontline immunotherapy for NSCLC — the tale of the tail
Chiang AC, Herbst RS. Frontline immunotherapy for NSCLC — the tale of the tail. Nature Reviews Clinical Oncology 2020, 17: 73-74. PMID: 31907372, DOI: 10.1038/s41571-019-0317-y.Peer-Reviewed Original Research
2019
P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer
Gutierrez M, Hellmann M, Gubens M, Aggarwal C, Tan D, Felip E, Lam W, Chiu J, Lee J, Yang J, Garon E, Basso A, Ma H, Fong L, Snyder A, Yuan J, Herbst R. P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s403. DOI: 10.1016/j.jtho.2019.08.822.Peer-Reviewed Original ResearchImmunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research 2019, 25: 4592-4602. PMID: 30824587, PMCID: PMC6679805, DOI: 10.1158/1078-0432.ccr-18-1538.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerPD-L1Lung cancerNonsquamous non-small cell lung cancerOngoing translational workPD-1 axisFirst-line therapyPD-L1 expressionProportion of patientsTumor mutational burdenAdvanced diseaseOverall survivalTumor inflammationMutational burdenPatientsNovel markerChemotherapyTherapyIndicative biomarkersCancerTranslational workBiomarkersSurvival
2018
60 How to Promote and Organize Clinical Research in Lung Cancer
Barlesi F, Mazieres J, Zhou Y, Herbst R, Zalcman G. 60 How to Promote and Organize Clinical Research in Lung Cancer. 2018, 628-634.e2. DOI: 10.1016/b978-0-323-52357-8.00060-3.Peer-Reviewed Original ResearchLung cancerClinical trialsNew clinical trial designsClinical trial designPotential therapeutic drugBasic science dataClinical researchersAppropriate trialsPreclinical dataPreventative optionsCertain therapiesTrial designNew treatmentsClinical researchPreclinical conceptsTherapeutic drugsCancerTrialsPatientsPersonalized medicineTherapyBiomarkers
2017
P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab Topic: Biomarkers
Mack P, Moon J, Herbst R, Kim E, Semrad T, Redman M, Tsai R, Solis L, Gregg J, Hatcher S, Varella-Garcia M, Hirsch F, Blanke C, Kelly K, Gandara D. P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab Topic: Biomarkers. Journal Of Thoracic Oncology 2017, 12: s967-s968. DOI: 10.1016/j.jtho.2016.11.1334.Peer-Reviewed Original ResearchP1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers
Rothberg B, Das R, Jackson L, Lazowski H, Bai Y, O'Neill D, Roberts S, Rothberg J, Herbst R, Kim A, Boffa D, Rimm D, Detterbeck F, Tanoue L. P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers. Journal Of Thoracic Oncology 2017, 12: s623-s624. DOI: 10.1016/j.jtho.2016.11.801.Peer-Reviewed Original ResearchP3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model Topic: IT Biomarkers
Lee J, Zhang Y, Choi J, Sharma R, Park H, Kaftan E, Papadimitrakopoulou V, Herbst R, Koo J. P3.02c-070 Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model Topic: IT Biomarkers. Journal Of Thoracic Oncology 2017, 12: s1319. DOI: 10.1016/j.jtho.2016.11.1865.Peer-Reviewed Original Research
2016
Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.
Hirsch F, Redman M, Herbst R, Kim E, Semrad T, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Kelly K, Gandara D. Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 9090-9090. DOI: 10.1200/jco.2016.34.15_suppl.9090.Peer-Reviewed Original ResearchPredictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.Peer-Reviewed Original Research
2015
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.
Horn L, Spigel D, Gettinger S, Antonia S, Gordon M, Herbst R, Sequist L, Chappey C, Kowanetz M, Sandler A, Soria J. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. Journal Of Clinical Oncology 2015, 33: 8029-8029. DOI: 10.1200/jco.2015.33.15_suppl.8029.Peer-Reviewed Original Research
2014
Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A
Kowanetz M, Rabe C, Xiao Y, Wu Q, Koeppen H, Leddy C, Patel R, Powderly J, Kohrt H, Gettinger S, Soria J, Herbst R, Desai R, Denker M, Ruppel J, Boe M, Nakamura R, Fu L, Sumiyoshi T, Mokatrin A, Shen X, Fine G, Chen D, Hegde P. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. Journal For ImmunoTherapy Of Cancer 2014, 2: p136. PMCID: PMC4288453, DOI: 10.1186/2051-1426-2-s3-p136.Peer-Reviewed Original Research
2013
Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.
Platt A, Elvin P, Morten J, Ji Q, Donald E, Womack C, Su X, Zheng L, Gladwin A, Vasselli J, Lee J, De Boer R, Herbst R. Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. Journal Of Clinical Oncology 2013, 31: 8045-8045. DOI: 10.1200/jco.2013.31.15_suppl.8045.Peer-Reviewed Original ResearchRET fusionsNSCLC trialsTumor samplesRET fusion genesFusion-positive patientsGene copy number gainRET protein expressionRECIST responseRadiologic evidenceEvaluable dataTumor shrinkageNSCLC tumorsBiomarker statusIHC analysisCopy number gainsRET amplificationRetrospective evaluationPatientsPotential associationVandetanibRET expressionPrevalenceProtein expressionPhase IIIBiomarkers
2011
Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.
Soulieres D, Wolf J, Shepherd F, Cappuzzo F, Bunn P, Herbst R, Hirsch F, Kerr K, Mitsudomi T, Tsao M, Yang C, Richardson F, Klughammer B, Wacker B, Sternberg D, Davies A. Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. Journal Of Clinical Oncology 2011, 29: 7533-7533. DOI: 10.1200/jco.2011.29.15_suppl.7533.Peer-Reviewed Original Research
2008
Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study
Tran H, Kim E, Lee J, Herbst R, Liu S, Wistuba I, Yan S, Mao L, Hong W, Heymach J. Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study. Journal Of Clinical Oncology 2008, 26: 8010-8010. DOI: 10.1200/jco.2008.26.15_suppl.8010.Peer-Reviewed Original ResearchBaseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC
Heymach J, Hanrahan E, Mann H, Langmuir P, Natale R, Johnson B, Herbst R, Ryan A. Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC. Journal Of Clinical Oncology 2008, 26: 8009-8009. DOI: 10.1200/jco.2008.26.15_suppl.8009.Peer-Reviewed Original Research
2007
P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC
Cleverly A, Bepler G, Oh Y, Burris H, Herbst R, Lahn M. P58 The use of a multi-analyte immunoassay panel (MAIP) to detect potential prognostic biomarkers associated with 2-month progression free survival rate in patients treated with Enzastaurin as 2nd and 3rd line therapy of NSCLC. European Journal Of Cancer Supplements 2007, 5: 30. DOI: 10.1016/s1359-6349(08)70079-x.Peer-Reviewed Original Research